A/Prof Aaron Hansen is committed to delivering the best possible care to his patients through a holistic, patient-centred and evidence-based approach. He is also passionate about continually enhancing his care through knowledge gained from clinical research and trials.
A/Prof Aaron Hansen is a medical oncologist consulting at Icon Cancer Centre Greenslopes. In 2004, he completed his Bachelor of Medicine, Bachelor of Surgery (MBBS) at the University of Queensland. He subsequently undertook specialist medical oncology training at the Princess Alexandra Hospital, followed by a fellowship in drug development at the Princess Margaret (PM) Hospital in Toronto, Canada.
In 2015, A/Prof Hansen was appointed as a staff medical oncologist at the PM and was the medical oncology lead for genitourinary cancers and co-chair of the head and neck disease site at the Canadian Clinical Trials Group. After a decade working in Canada, A/Prof Hansen returned to Brisbane, however he remains an active member of the US National Cancer Institute Recurrent Metastatic Head and Neck Cancer Taskforce.
Alongside his practice at Icon, A/Prof Hansen works as a medical oncologist at Greenslopes Private Hospital and Princess Alexandra Hospital. With a passion for providing education and mentorship to the next generation of medical oncologists and cancer researchers, he is also an associate professor at the University of Queensland’s School of Medicine.
A/Prof Hansen has a strong interest in clinical research and trials, with the aim of transforming care for cancer patients by increasing survival or improving quality of life. He has led multiple clinical trials across all phases, launched several investigator-initiated trials and has over 170 publications with many papers in peer-reviewed journals. A/Prof Hansen has also received various research awards, including the National Cancer Institute of Canada (NCIC) Phase II Program Team Award in 2016, Phase III Program Team Award and University of Toronto’s Young Investigator Award in 2021.
His clinical experience covers a broad range of solid tumour malignancies and he is recognised internationally as an expert in drug development, genitourinary cancer and head and neck cancer.